Recursion Pharmaceuticals reported a wider-than-expected loss and a sharp revenue decline for the second quarter of 2026. The company posted a loss of 25 cents per share, missing the Zacks Consensus Estimate of a loss of 23 cents, while total revenues fell 60% year over year to $7.67 million, well below the $14 million consensus. The revenue drop was driven by lower collaboration income from Roche and its subsidiary Genentech following the completion of certain project phases in the prior-year period. Recursion ended the quarter with $556.8 million in cash and equivalents, down from $665.2 million at the end of March, and expects its reserves to fund operations into early 2028. Shares fell 4.2% on the results and are down 22.5% year to date.
Recursion Pharmaceuticals IncMissed Q2 estimates with wider loss and 60% revenue decline
Harmony Biosciences Holdings
Repligen Corporation
Roche Holding AG